v3.25.4
Restructuring (Tables)
12 Months Ended
Dec. 28, 2025
Restructuring and Related Activities [Abstract]  
Summary of Severance Charges and Associated Spending
The following table summarizes the restructuring expenses for the fiscal years 2025, 2024 and 2023:
(Pre-tax Dollars in Millions)202520242023
MedTech Segment Surgery franchise(1)
$205
MedTech Segment Orthopaedics franchise(2)
307167319
Innovative Medicine Segment(3)
102479
Total Programs$512269798
(1)The fiscal year of 2025 included $76 million in restructuring, $122 million in Other income and expense and $7 million in Cost of products sold on the Consolidated Statement of Earnings
(2)The fiscal year of 2025 included $152 million in restructuring, $71 million in Other income and expense and $84 million in Cost of products sold on the Consolidated Statement of Earning The fiscal year of 2024 included $132 million in Restructuring and $35 million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal year of 2023 Included $40 million in Restructuring and $279 million in Cost of products sold on the Consolidated Statement of Earnings. This program was substantially completed in the fiscal year 2025.
(3)The fiscal year of 2024 included $102 million in Restructuring on the Consolidated Statement of Earnings. The fiscal year of 2023 included $449 million in Restructuring and $30 million in Cost of products sold on the Consolidated Statement of Earnings. This program was completed in the fiscal fourth quarter of 2024.